[Edaily Reporter Park Sun-Yeop ] #Aimed Bio Inc. announced on the 26th that it is set to receive a milestone royalty payment pursuant to the ODS025 technology transfer agreement signed with Boehringer Ingelheim International GmbH.
The amount received was not disclosed due to confidentiality clauses in the agreement. However, the company stated that the amount invoiced for the milestone royalty corresponds to at least 10% of its operating revenue of approximately 473억 won, based on its 2025 consolidated financial statements.
Aimed Bio Inc. received written notification of the milestone achievement from the counterparty on the same day and issued an invoice. The payment is expected to be made within 45 days of the counterparty’s receipt of the invoice.
The company explained that the technology transfer agreement may be terminated if future clinical trials, regulatory approvals, or commercialization do not materialize. However, it clarified that there is no obligation to refund the milestone royalty in the event of contract termination.
The agreement was signed on October 15, 2025, prior to Aimed Bio Inc.’s listing on the KOSDAQ market.